Cyclacel Pharmaceuticals ... (CYCC)
Cyclacel Pharmaceuticals Statistics
Share Statistics
Cyclacel Pharmaceuticals has 207.34M shares outstanding. The number of shares has increased by 14069.46% in one year.
Shares Outstanding | 207.34M |
Shares Change (YoY) | 14069.46% |
Shares Change (QoQ) | 3197.74% |
Owned by Institutions (%) | 0.23% |
Shares Floating | 205.34M |
Failed to Deliver (FTD) Shares | 1.51K |
FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 66.77K, so 0.59% of the outstanding shares have been sold short.
Short Interest | 66.77K |
Short % of Shares Out | 0.59% |
Short % of Float | 0.61% |
Short Ratio (days to cover) | 0.03 |
Valuation Ratios
The PE ratio is -0.07 and the forward PE ratio is -0.18. Cyclacel Pharmaceuticals's PEG ratio is 0.
PE Ratio | -0.07 |
Forward PE | -0.18 |
PS Ratio | 18.82 |
Forward PS | 0.4 |
PB Ratio | -0.37 |
P/FCF Ratio | -0.1 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cyclacel Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.59, with a Debt / Equity ratio of 0.
Current Ratio | 0.59 |
Quick Ratio | 0.59 |
Debt / Equity | 0 |
Debt / EBITDA | - |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $3.58K |
Profits Per Employee | $-934.33K |
Employee Count | 12 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -90% in the last 52 weeks. The beta is 0.16, so Cyclacel Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.16 |
52-Week Price Change | -90% |
50-Day Moving Average | 0.32 |
200-Day Moving Average | 0.79 |
Relative Strength Index (RSI) | 24.23 |
Average Volume (20 Days) | 554.58K |
Income Statement
In the last 12 months, Cyclacel Pharmaceuticals had revenue of 43K and earned -11.21M in profits. Earnings per share was -5.21.
Revenue | 43K |
Gross Profit | 43K |
Operating Income | -12M |
Net Income | -11.21M |
EBITDA | 0 |
EBIT | n/a |
Earnings Per Share (EPS) | -5.21 |
Balance Sheet
The company has 3.14M in cash and 0 in debt, giving a net cash position of 3.14M.
Cash & Cash Equivalents | 3.14M |
Total Debt | 0 |
Net Cash | 3.14M |
Retained Earnings | -439.49M |
Total Assets | 5.38M |
Working Capital | -6.35M |
Cash Flow
In the last 12 months, operating cash flow was -7.99M and capital expenditures 0, giving a free cash flow of -7.99M.
Operating Cash Flow | -7.99M |
Capital Expenditures | 0 |
Free Cash Flow | -7.99M |
FCF Per Share | -3.71 |
Margins
Gross margin is 100%, with operating and profit margins of -27916.28% and -26074.42%.
Gross Margin | 100% |
Operating Margin | -27916.28% |
Pretax Margin | -26074.42% |
Profit Margin | -26074.42% |
EBITDA Margin | n/a |
EBIT Margin | -27916.28% |
FCF Margin | -18581.4% |
Dividends & Yields
CYCC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CYCC is $11, which is 5138.1% higher than the current price. The consensus rating is "Buy".
Price Target | $11 |
Price Target Difference | 5138.1% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 18, 2023. It was a backward split with a ratio of 1:15.
Last Split Date | Dec 18, 2023 |
Split Type | backward |
Split Ratio | 1:15 |
Scores
Altman Z-Score | -119.98 |
Piotroski F-Score | 2 |